DURECT Corporation (DRRX)
0.72
0.00 (0.00%)
At close: Apr 17, 2025, 10:52 AM
0.00% (1D)
| Bid | 0.72 |
| Market Cap | 22.35M |
| Revenue (ttm) | 2.03M |
| Net Income (ttm) | -8.32M |
| EPS (ttm) | -0.6 |
| PE Ratio (ttm) | -1.2 |
| Forward PE | -2.57 |
| Analyst | Hold |
| Ask | 0.74 |
| Volume | 6,249 |
| Avg. Volume (20D) | 48,347 |
| Open | 0.72 |
| Previous Close | 0.72 |
| Day's Range | 0.71 - 0.74 |
| 52-Week Range | 0.70 - 1.88 |
| Beta | 0.89 |
About DRRX
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in...
Sector Healthcare
IPO Date Sep 28, 2000
Employees 21
Stock Exchange NASDAQ
Ticker Symbol DRRX
Website https://www.durect.com
Analyst Forecast
According to 2 analyst ratings, the average rating for DRRX stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 594.44% from the latest price.
Stock ForecastsNext Earnings Release
DURECT Corporation is scheduled to release its earnings on May 12, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
11 months ago
-14.02%
DURECT shares are trading lower after the company ...
Unlock content with
Pro Subscription
